you own 1% = about $3million dollars worth of AVXL ?? OR you meant $300k worth ?
According to CEO Hank Safferstein, Cognition's small molecule
drugs, taken orally, prevent toxic proteins
from binding to the brain. Pre-clinical data suggest
the drugs can reverse the effects Alzheimer's and sustain that reversal.
If proven, Cognition's approach has huge implications. There are currently no
therapeutics available to prevent the accumulation of the toxic proteins that cause
Alzheimer's cognitive impairment and, eventually, death. Alzheimer's is the sixth
leading cause of death in the U.S., and the number of patients is expected to rise
sharply as the population ages.
They are behind AVXL in terms of clinical trial progress. Not sure if science is the same.
wow chill a bit ctixers....decent run up last 2 days, but we have a LOT ways to go. Don't get too excited yet. I hope this volume is prelude to a partnership coming. Someone buying shares before announcement.
agree will see over 1 by summer though....$2 if partnership, $5 if 2A is good data.
it shows on yahoo finance...19M.
PBMD went up today on good results from 2nd TRIAL PATIENT. The phase II is not even over yet !!
Remember AVXL is open label...so we can get good news at any time on progress.
this is crazy...once AVXL gets orphan it should go up 100%.
but it does give a very strong case for partnerships...much more inventive for partners.
could be because 2a is not based on Epilepsy, but AZ...any good news, interim data on AZ would have had a much more positive effect.
that will give AVXL a 400 million market cap...still not expensive by any measure for the market they are going for, with very little competition, and current drugs very old.
how would they have money to burn on additional trials then ? partnership ? secondary offering ?
in addition to AZ ? Or are they ?
PTBI is gene therapy..and gene therapy does not work. Check out CLDN.